Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader

Boundless Bio's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy. Check ...
TMCnet

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver ...
technologynetworks

CRISPR Turns Oncogene Amplification Into a Cancer Weakness

A team from CNIO and CIEMAT eliminates cells that contain excessive copies of oncogenes using CRISPR gene editing. In cellular and animal models of neuroblastoma, small cell lung cancer and colon ...
ascopubs.org

Proto-oncogene HRAS transcript level and overall survival in stage II and III colorectal cancer.

Preclinical analysis and clinical validation to identify biomarkers for trifluridine/tipiracil (FTD/TPI) efficacy with or without bevacizumab in patients with metastatic colorectal cancer. This is an ...
ascopubs.org

Physical activity (PA) impact on metabolome and immunity of oncogene addicted non-small cell lung cancer (NSCLC): The EXcellenT trial.

Analysis of thromboembolic events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A single-center real-world study. This is an ASCO Meeting Abstract from the ...